The dataset from the NN102 SPRINT-MS project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov.
Dr. Robert Fox, PI of the NN102 SPRINT-MS study was the 2019 recipient of Cleveland Clinic's Sones Innovation Award for the advances in progressive multiple sclerosis made by the NN102 study. This award recognizes advances in innovation in the service of improved patient care. Congratulations to Dr. Fox and the NN102 SPRINT-MS team!
Applications for the NINDS-funded Clinical Trials Methodology Course (CTMC) 2019 are due February 28, 2019 at midnight. Application forms and additional details are available at http://neurotrials.training. Early applications may be considered for early acceptance.
The NN104 RHAPSODY primary manuscript has been published in the January 2019 print issue of Annals of Neurology. As the abstract notes, this trial was important for three reasons:
NN101 SMA was recently featured in the Cure SMA newsletter, highlighting the recently-published Recruitment & Retention paper.
Dr. Merit Cudkowicz, Principal Investigator of the NeuroNEXT CCC, was interviewed on CBS News' 60 Minutes on a feature about NFL star Tim Green coping with ALS. Her appearance begins at the 6:15 mark, and she discusses Mr. Green's prognosis and treatment.
The slide presentation from the 2018 NeuroNEXT Annual Meeting in Boston, MA October 18-19 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!
The dataset from the NN101 SMA project is now publicly available from the NINDS repository. Researchers interested in accessing this data should complete the NINDS Data Request Form and send it via email to the NINDS Clinical Research Liaison at: CRLiaison@ninds.nih.gov.
NINDS has issued a press release regarding the publication of the NN102 SPRINT-MS study results in the New England Journal of Medicine. The press release quotes NINDS Director Walter J. Kroshetz, MD, saying the NN102 SPRINT-MS findings "provide a glimmer of hope for people with a form of nultiple sclerosis that causes long-term disability but does not have many treatment options."
The results of the NN102 SPRINT-MS have been posted online at the New England Journal of Medicine.
The National Institute of Neurological Disorders and Stroke announced the renewal of the NeuroNEXT Network for an additional five years of funding.
The University of Iowa highlighted NeuroNEXT achievements in two campus publications: Iowa Now provides an overview of the ways the Network is accelerating the clinical trials process, and The Daily Iowan focuses on the ways NeuroNEXT is bringing together clinical sites and coordinating centers to advance neurological trials.
The Clinical Trials Methodology Course (CTMC) has begun their 2018 Webinar Series. These webinars are open to all. The course focues on the desing of early stage clinical trials for investigators focused on neurological illness and injury. The full scheduled may be viewed online: https://siren.network/training/ctmc/ctmc-webinars.
Neuro Central Podcast NC Talks featured an interview with Dr. Robert Fox, PPI of the NN102 SPRINT-MS study. Dr. Fox discussed trial results with the podcasters at the American Academy of Neurlogy's 70th Annual Meeting in Los Angeles, CA.
The American Academy of Neurology (AAN) Annual Meeting will begin April 21 in Los Angeles, CA. The following NeuroNEXT events and presentations will take place:
Network successes and the five-year renewal application were presented at the 2018 Annual Meeting of the American Society for Experimental Neurotherapeutics poster session.
Final results from the NN104 RHAPSODY trial, which were presented at the International Stroke Conference (ISC) 2018 as a closing event, were subsequently featured in ISC's Science News as Featured Science and on the American Stroke Association blog "Blogging Stroke."
Results of the NN104 study were covered in the San Diego Union-Tribune. The article details the development of 3K3A-APC, the study drug, originally developed by The Scripps Research Institute in La Jolla, CA.
The FDA released several guidance documents in February, 2018, three of which fall under the NeuroNEXT umbrella: 
ALS,
In the same issue where the NN101 SMA primary results were published, the Annals of Neurology also published an accompanying editorial.